This brand name is authorized in Canada, Hong Kong SAR China, Ireland, New Zealand, Poland, South Africa, Turkey.
The drug HIBERIX contains one active pharmaceutical ingredient (API):
1
|
UNII
FLV5I5W26R - HAEMOPHILUS INFLUENZAE TYPE B STRAIN 1482 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| J07AG51 | Haemophilus influenzae B, combinations with toxoids | J Antiinfectives for systemic use → J07 Vaccines → J07A Bacterial vaccines → J07AG Haemophilus influenzae B vaccines |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| CA | Health Products and Food Branch | 02239200 |
| HK | Department of Health Drug Office | 43304 |
| NZ | Medicines and Medical Devices Safety Authority | 9449 |
| PL | Rejestru Produktów Leczniczych | 100224274 |
| TR | İlaç ve Tıbbi Cihaz Kurumu | 8699522967360 |
| ZA | Health Products Regulatory Authority | 32/30.1/0349 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.